Journal of wound care
-
Journal of wound care · Nov 2016
Randomized Controlled TrialExtracorporeal shockwave therapy in the treatment of chronic diabetic foot ulcers: a prospective randomised trial.
To investigate the efficacy of extracorporeal shockwave therapy (ESWT) on healing chronic diabetic foot ulcers (DFU). ⋯ This randomised study indicates a potential beneficial effect of ESWT on ulcer healing as well as tissue oxygenation. Owing to weaknesses of the study and the fact that ulcer healing was not significantly improved in the intervention group compared with the control group, a larger randomised trial with blinded design is suggested.
-
Journal of wound care · Oct 2016
Case ReportsThoracoabdominal necrotising soft tissue infection secondary to enterocutaneous fistulae: a case report.
Necrotising soft tissue infection is a rare surgical emergency, which requires immediate and aggressive surgical debridement. Following control of the infection, patients are often left with large defects, with wound reconstruction and closure creating significant challenges. Here we describe a case of extensive thoracoabdominal necrotising soft tissue infection and provide a discussion on the standard of care and treatment based on a current literature review. ⋯ The authors have no personal financial or institutional interest in any of the drugs, materials, or devices used.
-
Journal of wound care · Jul 2016
Randomized Controlled Trial Multicenter StudyEvaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
The objective of this prospective, multicentre clinical study is to assess the application of MatriStem MicroMatrix (MSMM) and MatriStem Wound Matrix (MSWM) (porcine urinary bladder derived extracellular matrix) compared with Dermagraft (DG) (human fibroblast-derived dermal substitute) for the management of non-healing diabetic foot ulcers (DFUs). ⋯ The opinions expressed are those of the authors and not necessarily those of the Department of Veterans Affairs or the United States Government. T.W. Gilbert is employed as the Chief Science Officer and is a stockholder in ACell, Inc., which commercializes MatriStem Wound Matrix and MicroMatrix. None of the other authors have a conflict of interest to declare.
-
Journal of wound care · Jul 2016
Antimicrobial activity of a bioelectric dressing using an in vitro wound pathogen colony drip-flow reactor biofilm model.
We performed in vitro antibiofilm testing of a silver and zinc containing microcurrent generating bioelectric dressing (BED) against clinical wound pathogens to determine its efficacy in preventing biofilm formation under low shear and continuous flow conditions, simulating wound infection environments. ⋯ The opinions or assertions contained herein are the private views of the authors, based on scientific investigation, and are not to be construed as official or as reflecting the views of the Department of Defense, the United States Government or any of the authors' employers. Dr. Mina Izadjoo has served as a consultant to Vomaris Innovations Inc.